212 related articles for article (PubMed ID: 19307368)
1. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis.
Petraitis V; Petraitiene R; Hope WW; Meletiadis J; Mickiene D; Hughes JE; Cotton MP; Stergiopoulou T; Kasai M; Francesconi A; Schaufele RL; Sein T; Avila NA; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2009 Jun; 53(6):2382-91. PubMed ID: 19307368
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.
Calvo E; Pastor FJ; Salas V; Mayayo E; Guarro J
Mycopathologia; 2012 Apr; 173(4):251-7. PubMed ID: 22139415
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Rijs AJ; Verweij PE; Mouton JW
J Antimicrob Chemother; 2013 Feb; 68(2):385-93. PubMed ID: 23129729
[TBL] [Abstract][Full Text] [Related]
4. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.
Crandon JL; Banevicius MA; Fang AF; Crownover PH; Knauft RF; Pope JS; Russomanno JH; Shore E; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2009 Dec; 53(12):5102-7. PubMed ID: 19770284
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species.
Zhang M; Su X; Sun WK; Chen F; Xu XY; Shi Y
Mycopathologia; 2014 Feb; 177(1-2):11-8. PubMed ID: 24306184
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.
van de Sande WW; Mathot RA; ten Kate MT; van Vianen W; Tavakol M; Rijnders BJ; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2009 May; 53(5):2005-13. PubMed ID: 19237647
[TBL] [Abstract][Full Text] [Related]
7. Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
Siopi M; Siafakas N; Vourli S; Mouton JW; Zerva L; Meletiadis J
J Antimicrob Chemother; 2016 Nov; 71(11):3135-3147. PubMed ID: 27494912
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
Dowell JA; Schranz J; Baruch A; Foster G
J Clin Pharmacol; 2005 Dec; 45(12):1373-82. PubMed ID: 16291712
[TBL] [Abstract][Full Text] [Related]
9. Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.
Perkhofer S; Lass-Flörl C
Expert Opin Investig Drugs; 2009 Sep; 18(9):1393-404. PubMed ID: 19656074
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.
Kirkpatrick WR; Perea S; Coco BJ; Patterson TF
Antimicrob Agents Chemother; 2002 Aug; 46(8):2564-8. PubMed ID: 12121933
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole-micafungin combination therapy for acute lymphoblastic leukemia.
Okamoto T; Koh K; Takita J; Furuya A; Kato M; Ida K
Pediatr Int; 2010 Feb; 52(1):137-41. PubMed ID: 20158658
[No Abstract] [Full Text] [Related]
12. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitiene R; Petraitis V; Lyman CA; Groll AH; Mickiene D; Peter J; Bacher J; Roussillon K; Hemmings M; Armstrong D; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2004 Apr; 48(4):1188-96. PubMed ID: 15047519
[TBL] [Abstract][Full Text] [Related]
14. Non-clinical safety assessment and toxicokinetics of voriconazole and anidulafungin in the juvenile rat: a combination study design in support of a Paediatric Investigation Plan.
Cross DM; Chmielewski G; Lewis EM; Liu L; Modesitt MS; Ripp SL; Sawaryn CM; Bowman CJ
Regul Toxicol Pharmacol; 2012 Jun; 63(1):29-39. PubMed ID: 22343256
[TBL] [Abstract][Full Text] [Related]
15. In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus.
Krishnan Natesan S; Wu W; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):272-7. PubMed ID: 22897872
[TBL] [Abstract][Full Text] [Related]
16. Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Petraitis V; Petraitiene R; McCarthy MW; Kovanda LL; Zaw MH; Hussain K; Shaikh N; Maung BBW; Sekhon NK; Hope WW; Walsh TJ
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696236
[TBL] [Abstract][Full Text] [Related]
17. Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice.
Beinborn NA; Du J; Wiederhold NP; Smyth HD; Williams RO
Eur J Pharm Biopharm; 2012 Aug; 81(3):600-8. PubMed ID: 22569473
[TBL] [Abstract][Full Text] [Related]
18. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
[TBL] [Abstract][Full Text] [Related]
19. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
20. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Bell A; Callender DP; Sein T; Schaufele RL; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1998 Nov; 42(11):2898-905. PubMed ID: 9797223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
